NCT03215524 - A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

June 24, 2022

Study Completion Date

June 24, 2022

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

DCdP

Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide

BIOLOGICAL

DCd+P

Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression

Trial Locations (11)

Tom Baker Cancer Centre, Calgary

CrossCancer Institute, Edmonton

Fraser Valley Cancer Centre, Surrey

CancerCare Manitoba, Winnipeg

Saint John Regional Hospital, Saint John

QEII Health Sciences Centre, Halifax

Juravinski Cancer Centre (Hamilton Health Sciences Centre), Hamilton

The Ottawa Hospital, Ottawa

Thunder Bay Regional Health Sciences Centre, Thunder Bay

Princess Margaret Cancer Centre, Toronto

Saskatoon Cancer Centre, Saskatoon